Cancer patients well protected against COVID-19 with vaccines: study – clinical daily news

COVID-19 mRNA-based vaccines are effective in preventing infection in most cancer patients, according to a national study of veterans diagnosed with cancer in the past decade.

Researchers at Stanford University, Harvard University and the Department of Veterans Affairs studied the medical records of more than 180,000 VA patients who received cancer treatment between August 2010 and May 2021. Among them , approximately 113,000 were vaccinated with one of two mRNA vaccines approved by the Food and Drug Administration – Pfizer BioNTech and Moderna – between December 15, 2020 and May 4, 2021.

For each day of the study period, the researchers matched a patient who had been vaccinated with a peer with a similar medical history and demographic history who had not been vaccinated, comparing rates of COVID-19 infection. in each pair. They found that, overall, the vaccines were about 58% effective in preventing infection from two weeks after the second dose. But the vaccines were about 85% effective in people whose last cancer treatment ended six months or more before their first dose. Vaccines were about 63% effective in people whose cancer treatments ended three to six months before their first dose, and 54% in people whose treatments ended within three months of their first dose. . The results also suggest that the two vaccines were equally effective among this population, which was excluded from early vaccine trials.

“We know that in general, cancer patients with COVID-19 have poor outcomes,” said postdoctoral researcher Julie Tsu-Yu Wu, MD, Ph.D., one of the study’s lead authors. . “Our goal was to identify patients who might benefit from additional interventions such as a vaccine booster or who should be candidates after exposure to prophylactic interventions such as oral antivirals or monoclonal antibody treatments. But the main conclusion of our study is that vaccination against COVID-19 is an effective way to prevent infection in most cancer patients. “

Results were published in JAMA Oncology.

Comments are closed.